Firm Names IR Practice LaVoieHealthScience-IR (LHS-IR)
BOSTON – March 1, 2019 – LaVoieHealthScience (LHS), an integrated public and investor relations agency focused on advancing health and science innovations, today announced the hiring of Sharon Choe as Senior Vice President, Investor Relations & Business Development and the naming of its IR practice, LHS-IR. LHS-IR will focus on investor relations counsel, access and financial communications and Key Opinion Leader/Investor events, while the PR practice will continue to lead strategic communications engagements focused on story-telling including media and social media programming, medical/scientific communications, advocacy, spokesperson training and messaging. The firm expands its ability to provide integrated services to health and science clients worldwide.
This addition expands the firm’s presence from its strong roots in Boston/Cambridge, Massachusetts to the NYC financial market to fuel client demand for LHS’ integrated services model. Recent client wins with publicly-traded, global companies seeking US representation has accelerated LHS’ need to expand its talent. LHS’ integrated service model experienced 19 percent revenue growth over the previous fiscal year. In 2018, the firm added additional senior talent, including Doug Russell as Sr. VP & GM and Paul Sagan, AVP, Investor Relations and the promotion of Lisa DeScenza, VP, Integrated Communications.
Sharon joins the LHS team from The Ruth Group in NYC, where she has served as Senior Vice President since November 2015 until recently. Prior to her time at The Ruth Group, Sharon spent four years as Managing Director at Life Sci Advisors. As an industry veteran with extensive experience in life sciences, Sharon will use her expertise and network to expand business development for LHS, deploy best practices, hire talent and provide additional investor connections for LHS clients. Sharon will report to LHS President & CEO, Donna L. LaVoie and will be part of the Senior Leadership Team.
“We are proud to attract Sharon to our unique team of experts. Sharon will work with me and our senior team to scale the investor relations practice and build infrastructure. We will leverage our strong base of integrated public relations business, supporting leading innovators in our sector to extend our reach to the New York City financial market,” stated LaVoie.
Sharon also brings valuable experience on the buy side as a healthcare & biotech analyst at firms including UBS Asset Management, Credit Suisse Asset Management and BAM Capital LLC. “Sharon knows her way around the biotech community and Wall Street and I am certain she will play an important role with the rest of our team as we continue to add to our bench of talented specialized thinkers and executors in health and science communication,” concluded LaVoie.
“I am extremely excited by the opportunity to help lead LaVoieHealthScience’s strategic integration strategy of building a dedicated Investor Relations team to support the company’s award-winning public relations platform,” said Sharon. “I look forward to working with LHS’ talented team to advance the firm through its next phase of growth.”
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received 50+ award in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. The firm is known for its two trademarked methodologies for its messaging/positioning program (The LHS Immersion®) as well as how to tell your company story in 15 slides (The LHS Fifteen Slide Presentation®).
LaVoieHealthScience represents leaders such as, AC Immune SA, Biotechnology Industry Organization, Carmell Therapeutics, Genosco, Landos Biopharma, LEO Science & Tech Hub, NewLink Genetics, Newron Pharmaceuticals SpA, Origenis GmbH, PathMaker Neurosystems, Propanc BioPharma, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Torreya Partners, Triumvira Immunologics, Xontogeny LLC, and other emerging health and science companies.
Account Manager, PR and Marketing
Business Development Contact:
Senior Vice President,
Investor Relations & Business Development